Adage Capital Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Adage Capital Partners’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.9M	Buy	150,000 +100,000	+200%	+$7.53M	0.02%	679
2026 Q1	$3.75M	Sell	50,000 -90,000	-64%	-$7.1M	0.01%	796
2025 Q4	$11.1M	Sell	140,000 -1,175,000	-89%	-$88.5M	0.02%	643
2025 Q3	$86M	Sell	1,315,000 -2,485,000	-65%	-$121M	0.14%	152
2025 Q2	$150M	Buy	3,800,000 +2,724,400	+253%	+$89.2M	0.25%	74
2025 Q1	$32.5M	Buy	1,075,600 +800,600	+291%	+$26.2M	0.06%	313
2024 Q4	$9.61M	Sell	275,000 -225,000	-45%	-$8.41M	0.02%	619
2024 Q3	$20M	Sell	500,000 -300,000	-38%	-$14M	0.04%	450
2024 Q2	$38.1M	Sell	800,000 -200,000	-20%	-$8.2M	0.07%	276
2024 Q1	$43.4M	Sell	1,000,000 -385,300	-28%	-$18.4M	0.08%	256
2023 Q4	$70.1M	Buy	1,385,300 +318,300	+30%	+$15.2M	0.15%	154
2023 Q3	$48.4M	Buy	+1,067,000	New	+$44M	0.11%	204

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners's IONS Position: Q2 2026 in Review

Adage Capital Partners increased its Ionis Pharmaceuticals (IONS) stake by 200% in Q2 2026, buying an estimated $7.53M and bringing the position to 150,000 shares worth $11.9M. The position accounts for 0.02% of the portfolio, ranked #679.

Adage Capital Partners first reported a position in IONS in Q3 2023 and has held it in 12 quarters since. The position peaked at $150M in Q2 2025. 513 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Adage Capital Partners held 150,000 shares of Ionis Pharmaceuticals worth $11.9M as of Q2 2026.
Adage Capital Partners bought 100,000 Ionis Pharmaceuticals shares in Q2 2026, an estimated $7.53M.
Ionis Pharmaceuticals made up 0.02% of Adage Capital Partners's portfolio in Q2 2026, its #679 holding.
Adage Capital Partners first reported a position in Ionis Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Adage Capital Partners's Ionis Pharmaceuticals position peaked at $150M in Q2 2025.
513 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.